| Prevalence | Approximately 0.6-0.9 per 100,000 person-years |
| Estimated prevalence | 4-9 per 100,000 individuals |
| Age of onset | Typically 50-70 years (mean 63 years) |
| Female predominance | 1.2:1 female-to-male ratio |
| Family history | Less than 10% of cases have a family history |
| Environmental factors | Some studies suggest associations with head trauma, but evidence remains inconclusive[^8]. |
| Age | The strongest risk factor, with almost all cases developing after age 50. |
| Overlap with PSP and FTLD | CBD, PSP, and FTLD share common genetic and pathological features, suggesting overlapping risk factors[^9]. |
| [MAPT](/genes/mapt) | Microtubule-associated protein tau; H1 haplotype is major risk factor |
| [GRN](/genes/grn) | Progranulin; mutations cause FTLD-CBD |
| [LRRK2](/genes/lrrk2) | Leucine-rich repeat kinase 2; linked to familial parkinsonism |
| [Tau Protein](/proteins/tau) | Accumulates as 4R tau filaments in CBD |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
No AI portrait yet
No comments yet. Be the first to comment!
No comments yet. Be the first to comment!